HealthDay News — Fish oil supplementation is associated with atherothrombotic risk reduction in suspected coronary artery disease according to study findings published in The American Journal of Cardiology.
To determine if the use of fish oil supplementation (FOS) is linked to lower indices of atherothrombotic risk in patients with suspected coronary artery disease (sCAD), Christopher J. Franzese, of the Sinai Hospital in Baltimore, and colleagues conducted a subgroup analysis of consecutive patients with sCAD (n=600) enrolled in the Multi-Analyte, Thrombogenic, and Genetic Markers of Atherosclerosis study. Patients on FOS were compared with patients not on FOS.
FOS correlated with significantly increased eicosapentaenoic acid + docosahexaenoic acid content and with significantly lower triglycerides, total very low-density lipoprotein cholesterol, intermediate-density lipoprotein cholesterol, and AtherOx levels; these correlations were not seen in patients on lipid-lowering therapy.
Very low-density lipoprotein cholesterol, intermediate-density lipoprotein cholesterol, remnant lipoproteins, triglycerides, low-density lipoprotein cholesterol, AtherOx levels, collagen-induced platelet aggregation, thrombin-induced platelet-fibrin clot strength, and shear elasticity were lower for patients not on lipid-lowering therapy taking FOS.
There was no difference in ADP-induced aggregation between FOS groups for clopidogrel-treated patients. Regardless of lipid-lowering therapy, patients on FOS had lower urinary 11-dehydrothromboxane B2 levels.
“Future prospective studies to compare FOS with lipid-lowering therapy and to assess the independent effects of FOS on thrombogenicity are needed,” concluded the scientists.
Several authors disclosed financial ties to the pharmaceutical industry; one author disclosed holding patents in the area of personalized antiplatelet therapy and interventional cardiology.